Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease

a study on Alzheimer's Disease

Summary

Eligibility
for people ages 50-83 (full criteria)
Location
at San Diego, California
Dates
study started
completion around
Principal Investigator
by Neal Swerdlow, M.D., Ph.D.
Headshot of Neal Swerdlow
Neal Swerdlow

Description

Summary

The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's Disease will be tested

Keywords

Alzheimer Disease, Alzheimer's Disease, Alzheimer, AD, Alzheimer's, Memantine

Eligibility

For people ages 50-83

Inclusion:

  1. Alzheimer's Disease Research Center-confirmed diagnosis of AD
  2. Mini-Mental State Examination (MMSE) score 10-22 OR a Montreal Cognitive Assessment (MOCA) score of 15-24
  3. Age 50-83 y
  4. Knowledgeable caregiver
  5. Ambulatory
  6. Medically stable;
  7. Audiometric testing (detection < 40 db(A) at 1000 Hz)
  8. Informed consent

Exclusion:

  1. Active systemic illness (e.g. heart disease, liver failure, renal insufficiency, cancer, HIV, tuberculosis, Hepatitis C)
  2. Current psychiatric or neurologic illness other than AD
  3. History of vascular disease, myocardial infarction, cerebrovascular accidents, transient ischemic attack, seizure, head injury with loss of consciousness; substance dependence (including alcohol and Opioid)
  4. Past treatment with memantine; unable to tolerate acetylcholinesterase inhibitor
  5. Investigational drug treatment < 30 d of screening
  6. Current meds: amantadine, riluzole, other pro-cognitive medication, opioids
  7. Positive urine toxicology for non-prescribed psychoactive substance
  8. Actively enrolled in cognitive remediation therapy

Location

  • Clinical Teaching Facility (CTF-B102) at UCSD Medical Center accepting new patients
    San Diego California 92103 United States

Lead Scientist at UCSD

  • Neal Swerdlow, M.D., Ph.D.
    Neal Swerdlow, M.D., Ph.D. is Distinguished Professor of Psychiatry and Director of the Research Residency Track in the Department of Psychiatry at the University of California, San Diego, School of Medicine. Dr. Swerdlow graduated Summa Cum Laude, Phi Beta Kappa, from Amherst College (Neuroscience) in 1981, received his M.D. and Ph.D.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Diego
ID
NCT03703856
Phase
Phase 4 Alzheimer's Disease Research Study
Study Type
Interventional
Participants
Expecting 32 study participants
Last Updated
Contact us about this trial